ASLAN Pharmaceuticals Limited (ASLN)

July 26, 2024 - ASLAN Pharmaceuticals Limited was delisted.

0.600

-0.100 (-14.27%)

Inactive · Last trade price on Jul 18, 2024

ASLAN Pharmaceuticals Employees

ASLAN Pharmaceuticals had 35 employees as of December 31, 2023. The number of employees increased by 1 or 2.94% compared to the previous year.

Employees

35

Change (1Y)

1

Growth (1Y)

2.94%

Revenue / Employee

$342,857

Profits / Employee

-$1,000,765

Market Cap

1.70M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	35	1	2.94%
Dec 31, 2022	34	7	25.93%
Dec 31, 2021	27	9	50.00%
Dec 31, 2020	18	-	-

ASLN News

5 months ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July - Benzinga
5 months ago - ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation - GlobeNewsWire
5 months ago - ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal - GlobeNewsWire
7 months ago - ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference - GlobeNewsWire
8 months ago - ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
8 months ago - ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event - GlobeNewsWire
8 months ago - ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics - GlobeNewsWire
8 months ago - ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab - GlobeNewsWire